TiVo (NASDAQ:TIVO) and ITUS (ITUS) Head-To-Head Review
ITUS (NASDAQ:ITUS) and TiVo (NASDAQ:TIVO) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Valuation & Earnings
This table compares ITUS and TiVo’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TiVo||$826.46 million||1.46||-$37.95 million||$0.98||9.95|
TiVo pays an annual dividend of $0.72 per share and has a dividend yield of 7.4%. ITUS does not pay a dividend. TiVo pays out 73.5% of its earnings in the form of a dividend.
Institutional & Insider Ownership
4.7% of ITUS shares are held by institutional investors. Comparatively, 92.2% of TiVo shares are held by institutional investors. 23.6% of ITUS shares are held by company insiders. Comparatively, 3.5% of TiVo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares ITUS and TiVo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for ITUS and TiVo, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TiVo has a consensus price target of $22.00, indicating a potential upside of 125.64%. Given TiVo’s higher possible upside, analysts plainly believe TiVo is more favorable than ITUS.
TiVo beats ITUS on 7 of the 10 factors compared between the two stocks.
ITUS Company Profile
ITUS Corporation develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It also develops immuno-therapy drugs for the treatment of cancer. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. ITUS Corporation was founded in 1982 and is based in San Jose, California.
TiVo Company Profile
TiVo Corporation provides media and entertainment products for the consumer entertainment industry worldwide. The company operates in two segments, Product and Intellectual Property Licensing. The Product segment offers platform solutions, such as TiVo Service Platform, a cloud-based service that powers the TiVo Service client software, which operates on set-top boxes in consumer homes, as well as applications that operate on third party software platforms, such as iOS and Android; user experience solutions that allow service providers to customize elements of the interactive program guides for their customers, as well as to upgrade their programming features and services under the G-GUIDE brand; and CubiTV and TiVo Lite middleware solutions for pay TV service providers comprising cable, satellite, terrestrial, and telecommunications operators. It also provides software and services, including metadata, personalized content discovery and natural language voice, advanced media and advertising, and analog content protection services. As of December 31, 2017, this segment provided platform solutions to 22 million pay TV and consumer households. The Intellectual Property Licensing segment licenses its patent portfolio to the United States and international pay-television providers, mobile device manufacturers, consumer electronics manufacturers, and over-the-top video providers. The company was formerly known as Rovi Corporation and changed its name to TiVo Corporation in September 2016. TiVo Corporation was founded in 1983 and is based in San Jose, California.
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.